FDA approves Ardelyx public bsrela (tenapanor) for treatment of IBS-C adult patients
-
Last Update: 2020-06-08
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
The U.Sfda(http://approved the listing of the company's Ibsrela (tenapanor) to treat adult patients with constipation-type irritable bowel syndrome (IBS-C),(http:// announcedAbout Ibsrela
Ibsrela is a small molecule that locally inhibits sodium/hydrogen exchange protein 3 (NHE3) in the gastrointestinal tractIt stimulates intestinal peristalsis and reduces abdominal pain in patients with IBS-CIbsrela is a locally ineffective sodium/hydrogen exchange protein 3 (NHE3) inhibitorNHE3 is expressed on the surface of the small intestine and colon and is primarily responsible for absorbing sodium ions from foodBy inhibiting the function of NHE3, Ibsrela can reduce the absorption of sodium ions in the small intestine and colon, causing moisture to endocrine the intestines, which accelerates intestinal peristalsis and leads to loose nessIbsrela is hardly absorbed by the body, thus reducing the possibility of inhibiting NHE3 activity in other parts of the body, causing toxic side effectsThe approval was based on the results of two phase 3trial(http:// , and Ibsrela reached the main endpoint of the trial compared to the placebo group In the first clinical trial, the proportion of patients who achieved remission in the Ibsrela treatment group was 37%, the control group was 24%, and in the second clinical trial, the ibsrela group had a value of 27% and the control group was 19%
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
